SEARCH

SEARCH BY CITATION

References

  • 1
    Metra M, Ponikowski P, Dickstein K, et al; Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9:684694.
  • 2
    Damman K, Voors AA, Hillege HL, et al; CIBIS-2 Investigators and Committees. Congestion in chronic systolic heart failure is related to renal dysfunction and increased mortality. Eur J Heart Fail. 2010;12:974982.
  • 3
    Gheorghiade M, Shin DD, Thomas TO, et al. Congestion is an important diagnostic and therapeutic target in heart failure. Rev Cardiovasc Med. 2006;7(suppl 1):S12S24.
  • 4
    The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. Eur Heart J. 2008;29:23882442.
  • 5
    Lucas C, Johnson W, Hamilton MA, et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J. 2000;140:840847.
  • 6
    Guglin M. Key role of congestion in natural history of heart failure. Int J Gen Med. 2011;4:585591.
  • 7
    Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884888.
  • 8
    Bourge RC, Abraham WT, Adamson PB, et al; COMPASS-HF Study Group. Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study. J Am Coll Cardiol. 2008;51:10731079.
  • 9
    Drazner MH, Hellkamp AS, Leier CV, et al. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail. 2008;1:170177.
  • 10
    Stevenson LW; ESCAPE and COMPASS trials. Theodore E. Woodward Award: coming in out of the rain. Relieving congestion in heart failure. Trans Am Clin Climatol Assoc. 2009;120:177187.
  • 11
    Yu CM, Sanderson JE. Plasma brain natriuretic peptide—an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail. 1999;1:5965.
  • 12
    Dao Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide (BNP) in the diagnosis of heart failure in an urgent care setting. J Am Coll Cardiol. 2001;37:379385.
  • 13
    Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10:824839.
  • 14
    Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:11261130.
  • 15
    Monica R Shah. STARBRITE: a randomized pilot trial of BNP-guided therapy in patients with advanced heart failure. Circulation. 2006;114:528533.
  • 16
    Jourdain P, Jondeau G, Funck F, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP multicenter study. J Am Coll Cardiol. 2007;49:17331739.
  • 17
    Lainchbury JG, Troughton RW, Strangman KM, et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55:5360.
  • 18
    Pfisterer M, Buser P, Rickli H, et al; TIME-CHF Investigators. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301:383392.
  • 19
    Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol. 2011;58:18811889.
  • 20
    Porapakkham P, Porapakkham P, Zimmet H, et al. B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med. 2010;170:507514.
  • 21
    Rosenberg P, Yancy CW. Noninvasive assessment of hemodynamics: an emphasis on bioimpedance cardiography. Curr Opin Cardiol. 2000;15:151155.
  • 22
    Greenberg BH, Hermann DD, Pranulis MF, et al. Reproducibility of impedance cardiography hemodynamic measures in clinical stable heart failure patients. Congest Heart Fail. 2000;6:7480.
  • 23
    Barcarse E, Kazanegra R, Chen A, et al. Combination of B-type natriuretic peptide levels and non-invasive hemodynamic parameters in diagnosing congestive heart failure in the emergency department. Congest Heart Fail. 2004;10:171176.
  • 24
    Malfatto G, Blengino S, Perego GB, et al. Transthoracic impedance accurately estimates pulmonary wedge pressure in patients with decompensated chronic heart failure. Congest Heart Fail. 2012;18:2531.
  • 25
    Packer M, Abraham WT, Mehra MR, et al; Prospective Evaluation and Identification of Cardiac Decompensation by ICG Test (PREDICT) Study Investigators and Coordinators. Utility of impedance cardiography for the identification of short term risk of clinical decompensation in stable patients with chronic heart failure. J Am Coll Cardiol. 2006;47:22452252.
  • 26
    Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841848.
  • 27
    Catanzariti D, Lunati M, Landolina M, et al; Italian Clinical Service Optivol-CRT Group. Monitoring intrathoracic impedance with an implantable defibrillator reduces hospitalizations in patients with heart failure. Pacing Clin Electrophysiol. 2009;32:363370.
  • 28
    Malfatto G, Branzi G, Giglio A, et al. Transthoracic bioimpedance and brain natriuretic peptide levels accurately indicate additional diastolic dysfunction in patients with chronic advanced systolic heart failure. Eur J Heart Fail. 2010;12:928935.
  • 29
    Gerhard-Herman M, Gardin JM, Jaff M, et al; American Society of Echocardiography and the Society of Vascular Medicine and Biology. Guidelines for noninvasive vascular laboratory testing. J Am Soc Echocardiogr. 2006;19:955972.
  • 30
    Bruch C, Klem I, Breithardt G, et al. Diagnostic usefulness and prognostic implications of the mitral E/E' ratio in patients with heart failure and severe secondary mitral regurgitation. Am J Cardiol. 2007;100:860865.
  • 31
    Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. J Am Soc Echocardiogr. 2009;22:107133.
  • 32
    Enriquez-Sarano M, Tribouilloy C. Quantitation of mitral regurgitation: rationale, approach, and interpretation in clinical practice. Heart. 2002;88:13.
  • 33
    Thomas JD. Doppler echocardiographic assessment of valvar regurgitation. Heart. 2002;88:651657.
  • 34
    Mullens W, Borowski AG, Curtin RJ, et al. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation. 2009;119:6270.
  • 35
    Eurlings LW, van Pol PE, Kok WE, et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56:20902100.
  • 36
    Kamath SA, Drazner MH, Tasissa G, et al. Correlation of impedance cardiography with invasive hemodynamic measurements in patients with advanced heart failure: the BioImpedance CardioGraphy (BIG) substudy of the Evaluation Study of congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial. Am Heart J. 2009;158:217223.
  • 37
    Castellanos LR, Bhalla V, Isakson S, et al. B-Type natriuretic peptide and impedance cardiography at the time of routine echocardiography predict subsequent heart failure events. J Cardiac Fail. 2009;15:4147.
  • 38
    Pimenta J, Paulo C, Mascarenhas J, et al. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol. 2010;145:209214.
  • 39
    Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev. 2010;(8):CD007228.
  • 40
    Picano E, Frassi F, Agricola E, et al. Ultrasound lung comets: a clinically useful sign of extravascular lung water. J Am Soc Echocardiogr. 2006;19:356363.